artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography

AI-CAD marked axillary lymph node and region in right upper outer quadrant (arrows and thin line outlining both sites) and assigned an abnormality score of 28%.


August 11, 2021 — According to an open-access Editor’s Choice article in the American Journal of Roentgenology (AJR), artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography.

“After BCT, adjunct digital breast tomosynthesis (DBT) or AI-CAD reduced recall rates and improved accuracy in the ipsilateral and contralateral breasts compared with digital mammography (DM),” wrote lead investigator Jung Hyun Yoon. “In the ipsilateral breast, addition of AI-CAD resulted in lower recall rate and higher accuracy than addition of DBT.”

Yoon and colleagues’ single-center retrospective study included 314 women (mean age, 53.2 years; 4 with bilateral breast cancer) who underwent BCT followed by DBT (mean interval from surgery to DBT, 15.2 months). Three breast radiologists independently reviewed images in three sessions: DM, DM with DBT, and DM with AI-CAD. Recall rates and diagnostic performance were compared between these three sessions using readers’ mean results.

Among these 314 women, the mean ipsilateral breast recall rate among all three readers was lower (p<.001) for DM with AI-CAD (1.9%) than for DM with DBT (4.1%). In the ipsilateral breast, both mean accuracy (97.0% vs 94.8%, p=.02) and specificity (98.3% vs 96.1%, p=.003) were higher for DM with AI-CAD than for DM with DBT, respectively.

Acknowledging that data regarding other AI-CAD applications for the post-BCT breast are scarce, “our study shows that recall rates decrease significantly when DBT or AI-CAD are used as adjuncts to DM for surveillance of the ipsilateral and contralateral breasts in women with a personal history of breast cancer after BCT,” the authors of this AJR article concluded.

For more information: www.arrs.org


Related Content

News | RSNA

May 29, 2024 — The Radiological Society of North America (RSNA) has launched the 2024 RSNA Lumbar Spine Degenerative ...

Time May 29, 2024
arrow
News | Breast Imaging

May 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time May 28, 2024
arrow
News | FDA

May 22, 2024 — The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic Inc. BioZorb marker due to ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Breast Imaging

May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual ...

Time May 10, 2024
arrow
News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
News | Mammography

May 6, 2024 — Enable Me, a VELA Medical company, cited major new research by Siemens Healthineers entitled, “The future ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Subscribe Now